IP Library › Granted Patent US 10,022,434
Granted Patent B2
US 10,022,434 · App. 14/774,241 · Granted Jul 17, 2018

Influenza nucleic acid molecules and vaccines made therefrom

Inventors: David B. Weiner (Merion, PA); Jian Yan (Wallingford, PA); Matthew Morrow (Bala Cynwyd, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
A61K39/145A61K39/12C07K14/005C12N7/00A61K2039/53A61K2039/70C07K2319/02C07K2319/42C12N2760/16022C12N2760/16034C12N2760/16041C12N2760/16071C12N2760/16122C12N2760/16134C12N2760/16222C12N2760/16234C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,022,434
App. No.
14/774,241
Granted
Jul 17, 2018
Kind
B2
Abstract

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided.

Claims (29)

1. A multiple consensus subtype vaccine wherein the vaccine provides cross-reactivity against a variety of influenza strains, the vaccine comprising at least one consensus nucleic acid sequence encoding a hemagglutinin antigen, wherein said nucleic acid sequence is selected from the group consisting of:

SEQ ID NO:19 (H1Bris), a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:19, a fragment of SEQ ID NO:19 that is 300 or more nucleotides in length, a nucleic acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:19 that is 300 or more nucleotides in length;

SEQ ID NO:21 (H1TT), a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:21, a fragment of SEQ ID NO:21 that is 300 or more nucleotides in length, a nucleic acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:21 that is 300 or more nucleotides in length;

SEQ ID NO:23 (H3HA-2), a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:23, a fragment of SEQ ID NO:23 that is 300 or more nucleotides in length, a nucleic acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:23 that is 300 or more nucleotides in length;

SEQ ID NO:25 (BHA-2), a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:25, a fragment of SEQ ID NO:25 that is 300 or more nucleotides in length, a nucleic acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:25 that is 300 or more nucleotides in length;

SEQ ID NO:27 (H3HA-3), a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:27, a fragment of SEQ ID NO:27 that is 300 or more nucleotides in length, a nucleic acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:27 that is 300 or more nucleotides in length;

SEQ ID NO:29 (H3HA-4), a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:29, a fragment of SEQ ID NO:29 that is 300 or more nucleotides in length, a nucleic acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:29 that is 300 or more nucleotides in length;

SEQ ID NO:31 (BHA-3), a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:31, a fragment of SEQ ID NO:31 that is 300 or more nucleotides in length, a nucleic acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:31 that is 300 or more nucleotides in length;

SEQ ID NO:33 (BHA-4), a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:33, a fragment of SEQ ID NO:33 that is 300 or more nucleotides in length, a nucleic acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:33 that is 300 or more nucleotides in length, and any combination thereof.

2. The vaccine of claim 1 , further comprising an additional nucleic acid sequence encoding an hemagglutinin antigen selected from the group consisting of H1 hemagglutinin, H2 hemagglutinin, H3 hemagglutinin, and influenza B hemagglutinin, and any combination thereof.

3. The vaccine of claim 2 , wherein said additional nucleic acid sequence encoding H1 hemagglutinin is selected from the group consisting of a nucleic acid sequence encoding HS09, a nucleic acid sequence encoding H1U, and any combination thereof.

4. The vaccine of claim 2 , wherein the H3 hemagglutinin is selected from the group consisting of H3HA-1, H3HA-2, and any combination thereof.

5. The vaccine of claim 2 , wherein the influenza B hemagglutinin is selected from the group consisting of BHA-1, BHA-2, and any combination thereof.

6. The vaccine of claim 3 , wherein said nucleic acid sequence encoding HS09 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:2, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:2; a fragment of nucleic acid sequences encoding SEQ ID NO:2; and a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:2;

wherein said nucleic acid sequence encoding H1U comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:36, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:36; a fragment of nucleic acid sequences encoding SEQ ID NO:36; and a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:36.

7. The vaccine of claim 3 , wherein said nucleic acid sequence encoding H509 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:1; a fragment of SEQ ID NO:1; and a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:1;

wherein said nucleic acid sequence encoding H1U comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:35, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:35; a fragment of SEQ ID NO:35; and a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:35.

8. The vaccine of claim 4 , wherein H3HA-1 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:38, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:38; a fragment of nucleic acid sequences encoding SEQ ID N0:38; and a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:38;

wherein H3HA-2 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:24, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:24; a fragment of nucleic acid sequences encoding SEQ ID NO:24; and a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:24.

9. The vaccine of claim 4 , wherein H3HA-1 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:37, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:37; a fragment of SEQ ID NO:37; and a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:37;

wherein H3HA-2 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:23, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:23; a fragment of SEQ ID NO:23; and a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:23.

10. The vaccine of claim 5 , wherein BHA-1 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:14, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:14; a fragment of nucleic acid sequences encoding SEQ ID NO:14; and a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:14;

wherein BHA-2 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:26, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:26; a fragment of nucleic acid sequences encoding SEQ ID NO:26; and a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:26.

11. The vaccine of claim 5 , wherein BHA-1 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:13, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:13; a fragment of SEQ ID NO:13; and a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:13;

wherein BHA-2 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:25, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:25; a fragment of SEQ ID NO:25; and a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:25.

12. A method of inducing cross-reactivity against a variety of influenza strains in a mammal, the method comprising administering to the mammal in need thereof the vaccine of claim 1 .

13. The method of claim 12 , wherein each of the consensus hemagglutinin antigen is administered to the mammal separately.

14. The method of claim 12 , wherein each of the consensus hemagglutinin antigen is administered to the mammal simultaneously.

15. The vaccine of claim 1 , wherein said nucleic acid sequence is selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, and SEQ ID NO: 33.

Continuity (2)
Provisional Application 61787182 · Mar 15, 2013
Related Publication 20160022806A1 · Jan 28, 2016
Cited By (3)
US 12,606,804 US 12,616,745 US 12,728,160